|
000
| 01879cam 2200289za 4500 |
|---|
| 001 | 9.854785 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107155138 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 180606s2018 oncd ob f000 0 eng d |
|---|
| 020 | |a9780660261591 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH22-4/12-2018E-PDF |
|---|
| 245 | 00|aProtecting access to immune globulins for Canadians |h[electronic resource] : |bfinal report of the expert panel on immune globulin product supply and related impacts in Canada. |
|---|
| 246 | 30|aFinal report of the expert panel on immune globulin product supply and related impacts in Canada |
|---|
| 260 | |aOttawa : |bHealth Canada, |c2018. |
|---|
| 300 | |axvii, 167 p. : |bcol. charts. |
|---|
| 500 | |aIssued also in French under title: Protéger l'accès des Canadiens aux immunoglobulines : rapport final du comité d'experts sur l'approvisionnement en produits d'immunoglobuline et ses répercussions au Canada. |
|---|
| 500 | |a"May 2018." |
|---|
| 504 | |aIncludes bibliographic references. |
|---|
| 520 | |a"In response to concerns raised about market conditions for IG and the long-term sustainability of Canada's IG supply, Health Canada established the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada (the Panel) in July 2017. The mandate of the Panel was to assess the longterm security and sustainability of Canada's immune globulin product supply, and to examine the potential impact on the Canadian blood supply should plasma collection be permitted to expand significantly in Canada"--Exec. Summary, p. iv. |
|---|
| 692 | 07|2gccst|aInfectious diseases |
|---|
| 692 | 07|2gccst|aBlood supply |
|---|
| 710 | 1 |aCanada. |bHealth Canada. |
|---|
| 775 | 08|tProtéger l'accès des canadiens aux immunoglobulines |w(CaOODSP)9.854786 |
|---|
| 856 | 40|qPDF|s7.80 MB|uhttps://publications.gc.ca/collections/collection_2018/sc-hc/H22-4-12-2018-eng.pdf |
|---|